Avita.png
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
November 12, 2024 16:03 ET | AVITA Medical
AVITA Medical announces exclusive distribution agreement to expand the RECELL product platform to Australia and New Zealand.
Biostem main logo .png
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
November 12, 2024 07:29 ET | BioStem Technologies, Inc.
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
Biostem main logo .png
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
October 29, 2024 07:00 ET | BioStem Technologies, Inc.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All MAC Regions
Biostem main logo .png
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
October 28, 2024 13:58 ET | BioStem Technologies, Inc.
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
RedDress Logo.jpg
RedDress Announces ActiGraft Pro Added to WCA Formulary
October 24, 2024 08:40 ET | RedDress
RedDress today announced that ActiGraft Pro has been added to the Wound Care Advantage (WCA) Formulary after a comprehensive evaluation.
Skyquest Logo
Wound Care Market to Witness 3.1% CAGR by 2031 | SkyQuest Technology
October 17, 2024 17:00 ET | SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Oct. 17, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Wound Care Market will attain the value of USD 16.32 Billion by 2031, with a CAGR of 3.1% during the forecast period...
Biostem main logo .png
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
October 17, 2024 07:00 ET | BioStem Technologies, Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
Biostem main logo .png
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
October 15, 2024 07:00 ET | BioStem Technologies, Inc.
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
Biostem main logo .png
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
October 02, 2024 07:00 ET | BioStem Technologies, Inc.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
MRKS-Brand-Logo-Final-FullColor.png
Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft
October 01, 2024 08:37 ET | Merakris Therapeutics
Merakris to showcase Lyophilized Amnion Chorion, Dermacyte AC Matrix, at the Fall Symposium for Advanced Wound Care (SAWC) in Las Vegas on October 2-5.